CSI Market
Sign In | Register

Chinook Therapeutics Inc (KDNY) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access KDNY Annual Cash Flow →
Examining cash flow movements between Chinook Therapeutics Inc and Jun 30 2022 reveals how Jun 30 2023 allocates cash as operating conditions evolve.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2023)
6 Months 		(Mar 31 2023) (Dec 31 2022) (Sep 30 2022) (Jun 30 2022)
Operating Activities
Income-127.12
Depreciation & amortization0.00
Amortization of Other Assets0.87
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation17.10
Income (Loss) from Equity Method Investments-0.15
Fair Value of Assets Acquired0.00
Interest Expense-
Increase Decrease In Contract With Customer Liability-
Non Cash Lease Expense-
Depreciation And Amortization Excluding Amortization Of Intangible Assets2.35
Operating Lease Expense3.06
Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability-
Research And Development Expense Paid Through Issuance Of Common Stock-
Change In Fair Values Of Redeemable Convertible Preferred Stock Tranche Liability-
Change In Fair Value Of Contingent Consideration Liability And Contingent Value Rights Liability2.77
Increase Decrease In Operating Lease Liabilities-2.18
Income taxes0.00
Equity Method Investment, Realized Gain (Loss) on Disposal0.00
Increase (Decrease) in Accounts Receivable-2.01
Increase (Decrease) in Accounts Payable6.52
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-4.31
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-5.81
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-2.96
Discontinued operations0.00
Net Cash flow from Operating Activities-111.86
Investing Activities
Capital Expenditures-1.55
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities193.60
Payments to Acquire Marketable Securities-91.61
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities100.44
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock3.68
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-117.86
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents117.51
Capital Expenditures Incurred But Not Yet Paid0.34
Finance Lease Principal Payments-
Proceeds From At Market Sales Agreement Net Of Offering Costs-
Proceeds From Issuance Of Common Stock Pursuant To Subscription Agreements Prior To Merger Net Of Offering Costs-
Proceeds From Issuance Of Common Stock And Accompanying Pre Funded Warrants In Underwritten Public Offering Net Of Issuance Costs-
Proceeds From At Market Sales Agreement Net Of Issuance Costs19.60
Payment Of Previously Incurred Issuance Costs Related To Underwritten Public Offering-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities23.28
Effect of exchange rate on cash flow-0.14
Discontinued operations0.00
Free Cash Flow-113.41
Total Cash Flow11.71
4 historic quarters locked

Sign in to unlock the full Chinook Therapeutics Inc cash flow history.

Sign In Create Free Account

About Chinook Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-23-039041

Figures are derived from filed reports and may be restated. Historical data is subject to revision.